



Press Release November 30, 2023

Genovis AB changes Certified Adviser to Carnegie Investment Bank AB (publ)

Genovis AB today announces a change of Certified Adviser from Erik Penser Bank AB to Carnegie Investment Bank AB (publ). The reason for the change is that Carnegie Investment Bank AB has acquired certain operations, including the Certified Adviser operations, from Erik Penser Bank AB.

Genovis AB has entered into an agreement with Carnegie Investment Bank AB (publ) regarding the position as Certified Adviser. Carnegie Investment Bank AB (publ) will take over as Certified Adviser on November 30, 2023. Until then, Erik Penser Bank AB will continue to act as Certified Adviser to the company.

For additional information, please contact:

Fredrik Olsson, CEO, Genovis AB
T: +46 (0)70 276 46 56
E: fredrik.olsson@genovis.com

About Genovis AB

Genovis' business concept is to apply its knowledge and imagination to design and provide innovative tools for the development of the drugs of the future. Today Genovis sells several enzyme products known as SmartEnzymes™ all over the world in innovative product formats that facilitate development and quality control of biological drugs. The Group consists of Genovis AB and the wholly owned subsidiary Genovis Inc. (US). Genovis shares are listed on Nasdaq First North Growth Market and Carnegie Investment Bank AB (publ) is the Company's Certified Adviser,